Pharmaceutical Services Negotiating Committee Agenda

for the meeting to be held on 25th and 26th November 2020

Commencing at 9.00am via Zoom

Members:

Reena Barai, Richard Bradley, David Broome, Mark Burdon, Peter Cattee, Ian Cubbin, Marc Donovan, Samantha Fisher, Mark Griffiths, Jas Heer, Tricia Kennerley, Clare Kerr, Sunil Kochhar, Margaret MacRury, Rhys Martin (Observer), Fin McCaul, Niamh McMillan, Has Modi, Garry Myers, Bharat Patel, Indrajit Patel, Prakash Patel, Umesh Patel, Jay Patel, Janice Perkins, Adrian Price, Sian Retallick, Anil Sharma, Stephen Thomas, Faisal Tuddy, Gary Warner

Chair: Sue Killen

Wednesday 25th November

1.	Welcome from Chair	09:00 - 09:15
2.	Welcome and introduction from the Chief Executive	09:15 - 09:25
3.	Apologies for absence	
3.	Conflicts or declaration of interest	
4.	Minutes of the September meeting	
5.	Matters Arising (Appendix 01/11/2020)	
Act	ion:	
6.	Financial (i) Ongoing asks regarding the CPCF and C-19 costs (ii) Risks associated with the CPCF in Y3/4/5 (iii) New funding models	09:30 - 12:30
7.	Lunch	12:30 – 13:30
7.	Regulatory (i) Hub & Spoke (ii) EU Exit (iii) Supervision (iv) Consolidations and closures (v) DSPs - Essential and Advanced service provision	13:30 – 14:30
8.	Reputational risks (i) With patients	14:30 – 15:30

(ii) With politicians

9. Close of Day 1 and any outstanding business

13. Close of Day 2 and any outstanding business

Thursday 26th November				
10.	CPCF Service Delivery (i) What have we still left to do? (ii) Has anything changed over the past 12 months in terms of priorities/approac (iii) What would the Committee like to change/add?	09:00 – 10:15 h?		
11.	Reviewing our progress/performance (i) What does a good performance look like? (ii) What do we want to include in any annual review process? (iii) What are the risks?	10:15 - 11:30		
12.	Subcommittee reports	11:30 – 12:00		

15:30

12:00

Matters Arising

Meeting Reference	Matter Arising	Action
6 February 2020 (9.1)	A summary of the key points of the annual review to be circulated to the Committee and the office to approach other pharmacy bodies and invite feedback and contributions. The office will then write to the Government on these issues.	The Negotiating Team is currently reviewing this.
24 June 2020 (9.3)	Current and Future Funding - The working groups considered questions on a specific model and more general questions raised by it and it was agreed that further analysis of the model itself and the more general questions raised by it would be undertaken by the office starting in the summer.	This will be covered at the November PSNC meeting.
24 June 2020 (11.1)	The amended Risk Register will be circulated to the Committee.	Ongoing
25 June 2020 (12.3)	The Restoration and Recovery work with DHSC and NHSE&I, will continue over the summer and developments will be reported back to the Committee.	Ongoing
9 September 2020 (2.1)	In discussions with DHSC on: COVID-19 costs Seeking to reconcile the £370m Bid for additional funding for the contract sum	An update will be provided at the November PSNC meeting.
10 September 2020 (14.1)	1-to-1 meetings to be arranged between the Committee and Sue Killen.	Some meetings have already taken place. Shiné will be in touch to arrange a date if she hasn't already.

